WO2012092382A3 - Role of microrna in t cell immune response - Google Patents

Role of microrna in t cell immune response Download PDF

Info

Publication number
WO2012092382A3
WO2012092382A3 PCT/US2011/067615 US2011067615W WO2012092382A3 WO 2012092382 A3 WO2012092382 A3 WO 2012092382A3 US 2011067615 W US2011067615 W US 2011067615W WO 2012092382 A3 WO2012092382 A3 WO 2012092382A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
cell
mirna
inhibitor
cell activation
Prior art date
Application number
PCT/US2011/067615
Other languages
French (fr)
Other versions
WO2012092382A2 (en
Inventor
Millie Hughes-Fulford
Original Assignee
The United States Government As Represented By The Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Government As Represented By The Department Of Veterans Affairs filed Critical The United States Government As Represented By The Department Of Veterans Affairs
Publication of WO2012092382A2 publication Critical patent/WO2012092382A2/en
Publication of WO2012092382A3 publication Critical patent/WO2012092382A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides methods for increasing or decreasing T cell activation. The methods include contacting a T cell with an miRNA nucleic acid or an inhibitor of an miRNA. In some embodiments, the disclosed methods for increasing T cell activation include activating a T cell and contacting the activated T cell with an effective amount of an miRNA nucleic acid (such as one or more of miR-21, miR-101a, miR-377, let-7b, let-7c, or miR-574); or an inhibitor of an miRNA (for example, an inhibitor of one or more of miR-99a, miR-467b, miR- 467d, miR-199a, or miR-192), thereby increasing T cell activation, for example as compared to a control. In other embodiments, the disclosed methods for decreasing T cell activation include contacting a T cell (such as an activated T cell) with an effective amount of an inhibitor of an miRNA (for example, an inhibitor of one or more of miR-21, miR-101a, miR-377, let-7b, let-7c, or miR-574); or an miRNA nucleic acid (such as one or more of miR-99a, miR-467b, miR-467d, miR-199a, or miR-192), thereby decreasing the T cell activation, for example as compared to a control.
PCT/US2011/067615 2010-12-29 2011-12-28 Role of microrna in t cell immune response WO2012092382A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428112P 2010-12-29 2010-12-29
US61/428,112 2010-12-29

Publications (2)

Publication Number Publication Date
WO2012092382A2 WO2012092382A2 (en) 2012-07-05
WO2012092382A3 true WO2012092382A3 (en) 2012-08-23

Family

ID=45476693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/067615 WO2012092382A2 (en) 2010-12-29 2011-12-28 Role of microrna in t cell immune response

Country Status (1)

Country Link
WO (1) WO2012092382A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890789A1 (en) * 2012-08-31 2015-07-08 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
CN104474558B (en) * 2014-12-25 2018-02-06 宜春学院 Application of the microRNA in preparing synovium of joint apoptosis of fibroblasts biological agent
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
US11266676B2 (en) * 2016-10-27 2022-03-08 The Regents Of The University Of California MicroRNA in T cell activation
CN108359730A (en) * 2018-04-26 2018-08-03 东南大学 The application of miR-21 and its target gene in preparing diagnosis and/or prevention Osteoarthritis reagent or drug
EP3954773A1 (en) * 2020-08-12 2022-02-16 Royal College of Surgeons in Ireland Compositions and methods for the treatment of diseases by enhancing arginase 2 in macrophages

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
P. T. JINDRA ET AL: "Costimulation-Dependent Expression of MicroRNA-214 Increases the Ability of T Cells To Proliferate by Targeting Pten", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 2, 15 July 2010 (2010-07-15), pages 990 - 997, XP055022232, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1000793 *
SONKOLY E ET AL: "MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 126, no. 3, 1 September 2010 (2010-09-01), pages 581 - 589.E20, XP027255745, ISSN: 0091-6749, [retrieved on 20100731] *
SONKOLY ENIKÖ ET AL: "MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation.", SEMINARS IN CANCER BIOLOGY APR 2008 LNKD- PUBMED:18291670, vol. 18, no. 2, April 2008 (2008-04-01), pages 131 - 140, XP002671998, ISSN: 1096-3650 *
VAN DER FITS LESLIE ET AL: "MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY MAR 2011 LNKD- PUBMED:21085192, vol. 131, no. 3, 18 November 2010 (2010-11-18), pages 762 - 768, XP002671997, ISSN: 1523-1747 *
WEN PAN ET AL: "MicroRNA-21 and MicroRNA-148a Contribute to DNA Hypomethylation in Lupus CD4(+) T Cells by Directly and Indirectly Targeting DNA Methyltransferase 1", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 184, no. 12, 15 June 2010 (2010-06-15), pages 6773 - 6781, XP002637321, ISSN: 0022-1767, [retrieved on 20100517], DOI: 10.4049/JIMMUNOL.0904060 *
XUE Q ET AL: "Human activated CD4<+> T lymphocytes increase IL-2 expression by downregulating microRNA-181c", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 48, no. 4, 26 November 2010 (2010-11-26), pages 592 - 599, XP027578530, ISSN: 0161-5890, [retrieved on 20101229] *

Also Published As

Publication number Publication date
WO2012092382A2 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
WO2012092382A3 (en) Role of microrna in t cell immune response
WO2012134602A3 (en) Methods and systems for sequencing long nucleic acids
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
WO2014121287A3 (en) Selective antisense compounds and uses thereof
EP4269584A3 (en) Selective antisense compounds and uses thereof
WO2013188638A3 (en) Endoribonucleases and methods of use thereof
WO2012020234A3 (en) Integration of an energy storage device with a separate thermal process
WO2010099383A3 (en) Compositions and methods for ex vivo hepatic nucleic acid delivery
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2012078806A3 (en) Non-gaming on-line achievement awards
IL227426A0 (en) System, method, and article to prompt behavior change
WO2012076985A8 (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
WO2013096838A3 (en) Systems and methods for isolating nucleic acids
WO2012058494A3 (en) Isoprene synthase variants for improved production of isoprene
MX2014003979A (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
WO2010123728A3 (en) Method of making and using activated carbon-containing coated substrates and the products made therefrom
WO2012009272A3 (en) Pentose fermentation by a recombinant microorganism
EP3214678A4 (en) Electrode catalyst for fuel cell, production method thereof, fuel cell electrode catalyst layer containing said catalyst, fuel cell membrane-electrode assembly using said catalyst or catalyst layer, and fuel cell
WO2010056043A3 (en) Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
MX349801B (en) Nucleic acid enzyme substrates.
EP3349281A4 (en) Electrode catalyst layer for fuel cell, method for manufacturing same, membrane electrode assembly in which said catalyst layer is used, fuel cell, and vehicle
WO2012099832A3 (en) Enzymatic ligation of nucleic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808123

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11808123

Country of ref document: EP

Kind code of ref document: A2